(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
6 Tire Brands Reasonable for Seniors - 2The Significance of Prenuptial Arrangements in Separation Procedures
- 3Are IDF reservists properly armed during post-war operations?
- 4When darkness shines: How dark stars could illuminate the early universe
- 5As infant botulism cases climb to 31, recalled ByHeart baby formula is still on some store shelves
- Mossad unveils network of Hamas terror infrastructure across Europe
- These 2 moon rovers used cameras and lasers to hunt for simulated water ice — and one looks like WALL-E
- Vote In favor of Your Favored Distributed computing Administration
- Ukraine confirms defence and energy ministers at second attempt
- 5 Wellbeing Applications Assist You With remaining Fit
- ‘RuPaul's Drag Race’ Season 18: How to watch without cable, premiere time, cast list and more
- See the moon shine with Saturn in the southern sky after sunset Dec. 26
- Famous Rough terrain Vehicles for 2024
- Find Successful Magnificence Items for Sparkling Skin
